MX2022013886A - Anticuerpos contra coronavirus de tipo 2 causante del sindrome respiratorio agudo severo (sars-cov-2). - Google Patents

Anticuerpos contra coronavirus de tipo 2 causante del sindrome respiratorio agudo severo (sars-cov-2).

Info

Publication number
MX2022013886A
MX2022013886A MX2022013886A MX2022013886A MX2022013886A MX 2022013886 A MX2022013886 A MX 2022013886A MX 2022013886 A MX2022013886 A MX 2022013886A MX 2022013886 A MX2022013886 A MX 2022013886A MX 2022013886 A MX2022013886 A MX 2022013886A
Authority
MX
Mexico
Prior art keywords
cov
sars
antigen
antibodies against
against sars
Prior art date
Application number
MX2022013886A
Other languages
English (en)
Spanish (es)
Inventor
Davide Corti
Elisabetta Cameroni
Martina Beltramello
Dora Pinto
Gyorgy Snell
Florian A Lempp
Amalio Telenti
Matteo Samuele Pizzuto
Marco Anna De
Nadine Czudnochowski
Colin Havenar-Daughton
Fabrizia Zatta
Original Assignee
Vir Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vir Biotechnology Inc filed Critical Vir Biotechnology Inc
Publication of MX2022013886A publication Critical patent/MX2022013886A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2022013886A 2020-05-08 2021-05-07 Anticuerpos contra coronavirus de tipo 2 causante del sindrome respiratorio agudo severo (sars-cov-2). MX2022013886A (es)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202063022392P 2020-05-08 2020-05-08
US202063024372P 2020-05-13 2020-05-13
US202063027814P 2020-05-20 2020-05-20
US202063029338P 2020-05-22 2020-05-22
US202063031286P 2020-05-28 2020-05-28
US202063033045P 2020-06-01 2020-06-01
US202063036683P 2020-06-09 2020-06-09
US202063039939P 2020-06-16 2020-06-16
US202063046465P 2020-06-30 2020-06-30
US202063057767P 2020-07-28 2020-07-28
US202063090667P 2020-10-12 2020-10-12
US202063113450P 2020-11-13 2020-11-13
US202163153784P 2021-02-25 2021-02-25
US202163170368P 2021-04-02 2021-04-02
PCT/US2021/031442 WO2021226560A1 (en) 2020-05-08 2021-05-07 Antibodies against sars-cov-2

Publications (1)

Publication Number Publication Date
MX2022013886A true MX2022013886A (es) 2022-11-30

Family

ID=76250434

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013886A MX2022013886A (es) 2020-05-08 2021-05-07 Anticuerpos contra coronavirus de tipo 2 causante del sindrome respiratorio agudo severo (sars-cov-2).

Country Status (11)

Country Link
EP (1) EP4146690A1 (ko)
JP (1) JP2023525039A (ko)
KR (1) KR20230010676A (ko)
AU (1) AU2021268361A1 (ko)
BR (1) BR112022022523A2 (ko)
CA (1) CA3177169A1 (ko)
CL (1) CL2022003085A1 (ko)
CO (1) CO2022017670A2 (ko)
IL (1) IL297988A (ko)
MX (1) MX2022013886A (ko)
WO (1) WO2021226560A1 (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3872091T (lt) * 2020-02-26 2023-10-10 Vir Biotechnology, Inc. Antikūnai prieš sars-cov-2
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
EP4161960A1 (en) 2020-06-03 2023-04-12 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
CA3183367A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
IL300720A (en) 2020-08-26 2023-04-01 Flagship Pioneering Innovations Vi Llc Antigen binding molecules targeting Sars-cov-2
WO2022263638A1 (en) * 2021-06-17 2022-12-22 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
AU2022311906A1 (en) * 2021-07-14 2024-01-25 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2023201256A1 (en) * 2022-04-12 2023-10-19 Vir Biotechnology, Inc. High dose antibody therapies for sars-cov-2 infection
US11993644B2 (en) 2022-05-06 2024-05-28 Generate Biomedicines, Inc. Antigen binding molecules targeting SARS-CoV-2
WO2023224714A1 (en) * 2022-05-16 2023-11-23 Lawrence Livermore National Security, Llc Repaired therapeutic and prophylactic antibodies against sars-cov-2 variants
WO2023235827A2 (en) * 2022-06-03 2023-12-07 The Rockefeller University Coronavirus-inhibiting antibodies
WO2024006472A1 (en) 2022-06-30 2024-01-04 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
WO2024081269A1 (en) * 2022-10-10 2024-04-18 Dixit Rohan Therapeutic combinations and methods to treat long covid
WO2024102674A1 (en) 2022-11-13 2024-05-16 Generate Biomedicines, Inc. Antigen binding molecules targeting sars-cov-2
CN117362421A (zh) * 2022-12-02 2024-01-09 中国科学院微生物研究所 一种针对新冠病毒rbd的广谱单克隆抗体、其制备方法及应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
DE602004030700D1 (de) 2003-09-24 2011-02-03 Kyowa Hakko Kirin Co Ltd Rekombinanter antikörper gegen humanen insulin-like growth factor
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
BR112016015140A2 (pt) 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
JP6587696B2 (ja) 2015-05-13 2019-10-09 ズムトール バイオロジクス、インコーポレイテッド アフコシル化タンパク質、前記タンパク質を発現する細胞、及び関連する方法
WO2019024979A1 (en) 2017-07-31 2019-02-07 Institute For Research In Biomedicine FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
SG11202002261VA (en) 2017-09-22 2020-04-29 Wuxi Biologics Ireland Ltd Novel bispecific polypeptide complexes

Also Published As

Publication number Publication date
BR112022022523A2 (pt) 2023-01-10
CO2022017670A2 (es) 2023-03-07
EP4146690A1 (en) 2023-03-15
JP2023525039A (ja) 2023-06-14
CL2022003085A1 (es) 2023-09-01
KR20230010676A (ko) 2023-01-19
WO2021226560A1 (en) 2021-11-11
CA3177169A1 (en) 2021-11-11
AU2021268361A1 (en) 2022-12-08
IL297988A (en) 2023-01-01

Similar Documents

Publication Publication Date Title
MX2022013886A (es) Anticuerpos contra coronavirus de tipo 2 causante del sindrome respiratorio agudo severo (sars-cov-2).
MX2022010537A (es) Anticuerpos contra el coronavirus de tipo 2 causante del sindrome respiratorio agudo severo (sars-cov-2) y metodos de uso de los mismos.
BR112022015374A2 (pt) Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
CR20200465A (es) Agentes anticuerpos anti-cd25
WO2019014328A3 (en) AGONISTIC ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
BR112022020706A2 (pt) Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
AU2017297757A1 (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
ZA202100676B (en) Anti-tigit antibody and uses thereof
WO2016154003A8 (en) Neutralizing antibodies to gp120 and their use
WO2019165122A8 (en) Neutralizing antibodies to hiv-1 env and their use
WO2021231237A3 (en) Antibodies for sars-cov-2 and uses thereof
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
MX2020013324A (es) Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos.
BR112021016272A2 (pt) Receptores de antígeno quimérico anti-dll3 humanizados e usos dos mesmos
WO2022067269A3 (en) Antibodies against sars-cov-2
MX2022007231A (es) Anticuerpos anti-mertk y metodos de uso de los mismos.
MX2022016544A (es) Agentes de union a lair-1 y metodos para su uso.
ZA202201464B (en) Anti-tigit antibodies and application thereof
MX2022012628A (es) Anticuerpos anti-phf-tau y usos de estos.
MX2023005654A (es) Anticuerpos ampliamente neutralizantes contra neuraminidasa de la influenza.
WO2022204713A3 (en) Antibodies to sars-cov-2
MX2022003719A (es) Anticuerpos anti-il-27 y sus usos.
PH12020551454A1 (en) Anti-cd25 for tumour specific cell depletion
WO2022221844A3 (en) Improved chimeric antigen receptors and uses thereof
WO2023230445A3 (en) Broadly neutralizing antibodies against influenza neuraminidase